Characterization of an Antibody Depletion Assay for Analysis of Bactericidal Antibody Specificity
- 1 December 2009
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 16 (12) , 1789-1795
- https://doi.org/10.1128/cvi.00255-09
Abstract
Serum bactericidal antibodies are important for protection against systemic Neisseria meningitidis infections. Consequently, identifying the specific targets of bactericidal antibodies is important for understanding protective immunity to meningococcal disease and for vaccine development and evaluation. We have developed a new assay that can be used to investigate the specificity of serum bactericidal antibodies. Prior to testing for bactericidal activity, antibodies specific for a given antigen or group of antigens are depleted from a serum sample by incubation with the antigen(s) bound to the wells of a 96-well microplate. A dilution series of the antigen is bound to the plate to assess the effectiveness of the antigen in removing the bactericidal antibodies. Removal of antibodies with solid-phase antigen prior to bactericidal testing avoids depletion of complement by soluble immune complexes that can form when soluble antigen is present in the bactericidal test mixture (direct inhibition). The parameters associated with this assay are investigated and compared with those associated with a direct-inhibition assay. The bactericidal depletion assay can be an effective tool for studying the specificity of serum bactericidal antibodies.Keywords
This publication has 17 references indexed in Scilit:
- A generic mechanism inNeisseria meningitidisfor enhanced resistance against bactericidal antibodiesThe Journal of Experimental Medicine, 2008
- Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A MeningococciClinical and Vaccine Immunology, 2008
- Additive and Synergistic Bactericidal Activity of Antibodies Directed against Minor Outer Membrane Proteins of Neisseria meningitidisInfection and Immunity, 2007
- Comparison of Phenotypically Indistinguishable but Geographically Distinct Neisseria meningitidis Group B Isolates in a Serum Bactericidal Antibody AssayClinical and Vaccine Immunology, 2007
- Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy AdolescentsClinical and Vaccine Immunology, 2007
- Towards an improved serogroup BNeisseria meningitidisvaccineExpert Opinion on Biological Therapy, 2005
- Importance of Complement Source in Measuring Meningococcal Bactericidal TitersClinical and Diagnostic Laboratory Immunology, 2001
- Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome SequencingScience, 2000
- Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccineVaccine, 1996
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969